August 13, 2024 - by Ashlee Vogenthaler

BioStem (BSEM) Reports Record Second Quarter Revenue of $74.5M with $116.4M Generated for the First Half of 2024

13 August 2024

New York, August 13, 2024 - PRISM MarketView - Advanced wound care technology company BioStem Technologies (BSEM) announced its second quarter financials and achieved a second consecutive record quarter for the company. BioStem reported $74.5M in revenue for the second quarter compared to $1M in 2023, which totaled first half revenue for the year to $116.4M. Gross profit was $70.7 million, or 95% of net revenue, and the Company generated net income of $6.4 million, or $0.39 per share, versus a net loss of ($2.8) million in the three-month period of 2023. Additionally, BioStem’s cash balance increased at the end of Q2 to $6.6M, which was an approximate $6M increase from the previous quarter as margins remained strong and sustainable.

BioStem Technologies - Prism MarketView

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercializat

BioStem’s AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024. In June, the company reported breakthrough results on AmnioWrap2 that were published in the peer-reviewed journal, Health Science Reports which found BioStem’s products offered better treatment efficacy in general would closure. In July, BioStem received Institutional Review Board (IRB) approval to initiate a clinical study evaluating AmnioWrap2 in diabetic foot ulcers to demonstrate the efficacy of the product to advance expanded payer insurance coverage.

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closurePOMPANO BEACH, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its place

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

POMPANO BEACH, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ul

On its conference call, BioStem mentioned they are currently in the process of updating their registration with Q2 numbers, have filed an application with NASDAQ to uplist and are pending review by the SEC on their Form 10. The company expects an update on this in the next 60 – 90 days.

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.

About PRISM MarketView:

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.

To see this content properly accept cookies.

Disclaimer:

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

Contact:

PRISM MarketView
info@prismmarketview.com
646-863-6341

Prism MarketView | Stock Market News & Investment Opportunities

To see this content properly accept cookies.